Companies to collaborate in developing wearable products for irregularity
Pasadena, CA, June 23, 2017– Alpha Logic Inc. today announces the completion of a strategic agreement with GlaxoSmithKline Inc. to conduct ground breaking research on the use of the AbStats™ system for tracking and treating the more than 1 Billion individuals with chronic irregularity and irritable bowel syndrome (IBS) worldwide. The AbStats system is a wearable biosensor with imbedded artificial intelligence (AI) that allows for real-time continuous data on the function of the GI tract.
“The commitment of GlaxoSmithKline to bringing products to those suffering from digestive conditions like diarrhea, constipation and IBS is a perfect match to marry the AbStats ™ technology. This collaboration has the potential to develop a tool to reach the tens of millions of patients suffering from these chronic gastrointestinal disorders.” Said Ken Beres President Alpha Logic Inc.
GlaxoSmithKline’s line of Nutrition and Gastro Intestinal OTC products including Benefiber® and Tums® provide consumers with relief and control for common complaints. It is the belief of the two companies that utilizing real time surveillance in the form of the AbStats™ system could add an additional tool for using these products.
Alpha Logic Inc. Is a private medical technology company developing and marketing technologies built off the patent pending AbStats™ technology exclusively licensed from the UCLA wireless health institute. AbStats™ technology use Artificial Intelligence generated algorithms to detect minute movements in the GI tract to give physicians and patients a first ever, dynamic real-time and continuous assessment of GI function. AbStats has been shown in two peer reviewed published papers to be accurate and predictive in assessing GI function.